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   ABSTRACT   
  Objective      To evaluate abatacept treatment over 3 years 
in patients with rheumatoid arthritis (RA) refractory to 
methotrexate (MTX).   
  Methods      Patients randomised to abatacept or 
placebo (+MTX) during the 1-year double-blind 
period of the   A  batacept in   I  nadequate responders to 
  M  ethotrexate (AIM) trial received open-label abatacept 
(+MTX) in the long-term extension (LTE). Safety 
was assessed for patients who received ≥1 dose of 
abatacept, regardless of randomisation group. Efﬁ  cacy 
was assessed for patients randomised to abatacept 
who entered the LTE.   
  Results      433 and 219 patients were randomised and 
treated with abatacept or placebo, respectively; 378 and 
161 entered the LTE. At year 3, 440/539 patients were 
ongoing. No unexpected safety events were observed in 
the LTE. By year 3, incidence rates of adverse event and 
serious adverse events were 249.8/100 and 15.1/100 
patient-years, respectively. Incidence rates were generally 
stable over time. At year 3, 84.8%, 63.4% and 37.5% of 
patients achieved American College of Rheumatology 
(ACR) criteria of 20, 50 and 70, respectively, compared 
with 82.3%, 54.3% and 32.4% of patients at year 1. 
Mean changes in Genant-modiﬁ  ed Sharp scores were 
reduced progressively over 3 years, with signiﬁ  cantly 
greater inhibition during year 3 compared with year 2 
(p=0.022 for total score).   
  Conclusion      In MTX-inadequate responders with RA, 
abatacept provided consistent safety and sustained 
efﬁ  cacy over 3 years. The data suggest an increasing 
inhibitory disease-modifying effect on radiographic 
progression.      
  INTRODUCTION 
  Rheumatoid arthritis (RA) is a chronic disorder 
requiring long-term treatment. As joint dam-
age in patients with RA is often progressive and 
patients remain on treatment for extensive peri-
ods, long-term follow-up is required to assess efﬁ  -
cacy and safety of interventions. In the phase III 
AIM (  A  batacept in   I  nadequate responders to 
  M  ethotrexate (  M  TX)) trial,  1   abatacept demon-
strated sustained clinical efﬁ   cacy and consistent 
safety over 2 years of treatment.  2   An increasing 
inhibition of radiographic progression was also 
reported over each year.  3   In this paper we report 
the safety, efﬁ  cacy, inhibition of radiographic pro-
gression and impact on health-related quality of 
life (HRQoL) of abatacept over 3 years.   
  METHODS 
  Study  design 
  Patients who completed the double-blind period 
of the AIM trial  1   were eligible to enter the open-
label long-term extension (LTE), where patients 
originally randomised 2:1 to either abatacept or 
placebo (+MTX) received open-label abatacept 
(approximately 10 mg/kg according to weight 
range) every 28 days.  2   During the LTE, patients 
continued taking MTX; adjustments to MTX dose 
were permitted in addition to other concomi-
tant medications, including background disease-
modifying antirheumatic drugs (DMARDs). The 
cumulative period included the 1-year double-
blind period plus 2 years of the LTE (3 years in 
total). During the ﬁ  rst 12 months both patients 
and physicians were blinded to treatment assign-
ment; radiologists were blinded to the treatment 
and order of time points throughout.   
  Safety  assessments 
  Safety was reported according to the Medical 
Dictionary for Regulatory Activities. For patients 
who prematurely discontinued, adverse events 
(AEs) were recorded at days 28, 56 and 85 after the 
last abatacept dose.   
  Clinical  efﬁ  cacy, physical function and HRQoL 
assessments 
  Clinical efﬁ  cacy was assessed using the American 
College of Rheumatology (ACR) criteria and 
Disease Activity Score in 28 joints (DAS28, based 
on C reactive protein (CRP) levels; scale of 0–9.3). 
Physical function and HRQoL were evaluated using 
the Health Assessment Questionnaire-Disability 
Index (HAQ-DI; scale of 0–3, response deﬁ  ned 
as a decrease of ≥0.3 from baseline) and Short 
Form (SF)-36 (scale of 0–100, clinically meaningful 
improvement deﬁ  ned as change of ≥3 units from 
baseline), respectively, as previously described.  1     
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 Table  1     Summary of adverse events and malignancy type for all patients 
who received one dose of abatacept during 3 years of the study   
  Event, IR/100 patient-years   Double-blind period 
abatacept+MTX 
(n=433) 
  Cumulative  period *  
abatacept+MTX 
(n=594) 
Total AEs 303.4 249.8
Total SAEs 17.7 15.1
Infections 90.5 70.8
Serious infections 4.2 3.2
Malignancies 1.7 1.5
Autoimmune events 2.5 2.2
Malignancy type, n
  Total patients with malignancies 7 24
  Non-melanoma skin cancer 5 15
  Basal cell carcinoma 4 12
  Squamous cell carcinoma 1 3
 Solid  organ 0 6
 Lung 0 3
 Prostate 0 1
 Endometrial 0 1
 Melanoma 0 1
 Haematological 2 3
 Lymphoma 1 2
 Myelodysplastic  syndrome 1 1
   *       Data are presented for all patients who participated in the long-term extension 
regardless of randomised double-blind treatment group.   
    AE, adverse event; IR, incidence rate; MTX, methotrexate; SAE, serious adverse event.     
  Radiographic  assessments 
  Radiographic assessments were performed at baseline and years 
1, 2 and 3 (or within ≤28 days of discontinuation).  3   At year 3, 
radiographs from baseline and years 1 and 2 were re-read in ran-
dom order by two independent readers, blinded to treatment and 
order of time points. The Genant-modiﬁ  ed Sharp scoring system 
assessed radiographs of joints in the hands, wrists and feet for 
changes in total score (TS; non-progression deﬁ  ned as mean change 
from baseline of ≤0), erosion score (ES) and joint space narrowing 
(JSN) score (maximum scores 290, 145 and 145, respectively).  2     3     
  Statistical  analysis 
  Safety analyses included all patients who received ≥1 dose of 
abatacept in the cumulative period, regardless of randomisation 
group (abatacept or placebo). Incidence rates (IRs)/100 patient-
years of exposure were calculated as previously described.  2   
  Clinical efﬁ  cacy and radiographic progression are presented 
for patients originally randomised to abatacept who entered the 
LTE and received ≥1 dose of abatacept, with data available at 
the visit of interest (as-observed). For assessment of the ACR 
data set, the tender and swollen joint counts and ﬁ  ve compo-
nents were scored as ‘0’ when the patient did not satisfy a com-
ponent criterion, ‘1’ when the patient did satisfy a component 
criterion or missing (‘−’) when no data were available. Patients 
were only included in the as-observed analysis for each ACR 
response (ACR 20, 50 or 70) when they had either joints of ‘1’ 
and at least three (of the ﬁ  ve) components of ‘1’ or joints of ‘0’ 
and at least three (of the ﬁ  ve) components of ‘0’. Thus, for every 
patient on every visit day, ACR 20, 50 and 70 responses were 
assessed independently, resulting in different numbers for ACR 
responses at each given time point. 
  For mean changes in radiographic scores, all patients with radio-
graphs at baseline who received ≥1 dose of abatacept in year 2 
were included in the year 3 analysis. Patients who discontinued 
during the LTE were requested to return for follow-up radiogra-
phy at their next annual visit, regardless of subsequent prescribed 
treatment. Radiographs were taken at the time of discontinuation 
in those patients who declined to return for an annual visit and 
their next annual assessment imputed with linear extrapolation 
based on the last available annual visit and assessment at discon-
tinuation. A non-parametric analysis was performed to compare 
the distribution of mean change scores (TS, ES and JSN score).  2     3       
  RESULTS 
    Patient disposition, baseline characteristics and demographics 
  Of the 433 and 219 patients randomised to abatacept and pla-
cebo, respectively, 82.3% and 80.1% of these were ongoing 
at year 3. For the 433 randomised abatacept-treated patients, 
the retention rate at year 3 was 72% with 11.1% (48/433), 
12.2% (46/378) and 6.3% (21/332) of patients discontinuing, 
respectively, during years 1, 2 and 3; 5.8% (25/433) and 8.8% 
(38/433) of these patients discontinued due to lack of efﬁ  cacy 
and AEs, respectively, over the 3 years (see   ﬁ  gure 1   in online 
supplement).   
  Baseline demographics and clinical characteristics of patients 
entering the LTE were comparable between treatment groups, as 
previously reported.  1     2   Overall, mean age and disease duration 
were 50.8 and 8.5 years, respectively. The mean (SD) Genant-
modiﬁ  ed Sharp TS was 45.2 (35.1) and DAS28 (CRP) was 6.4 
(0.8). All patients received concomitant MTX during the study. 
For patients randomised to abatacept who entered the LTE, 
mean MTX doses decreased from 15.1 mg at baseline to 14.4, 
14.3 and 14.2 mg at years 1, 2 and 3, respectively.   
  Safety 
  Overall  safety 
  During the 3-year cumulative period mean abatacept exposure 
was 34.3 months. Of patients originally randomised to abata-
cept, a total of 569 patients (96%) experienced an AE with an 
IR of 249.8/100 patient-years; a similar IR was reported in the 
double-blind period (  table 1  ). The type and incidence of the 
most commonly reported AEs during the cumulative period 
were similar to those reported in the double-blind period,  1     2   as 
were the IRs of serious AEs (SAEs). In the cumulative period, 55 
and 36 patients discontinued due to AEs and SAEs, respectively. 
Cardiac disorders were reported in 68 patients (11.4%) during 
the cumulative period at an IR of 4.37/100 patient-years.   
  Ten deaths were reported in the cumulative period in patients 
who had received ≥1 dose of abatacept; bronchopulmonary asper-
gillosis in year 1 (n=1), myocardial ischaemia with postprocedural 
complications, lobar pneumonia and lung cancer in year 2 (n=1 
for all) and, in year 3, pneumonia/sepsis, malignant melanoma 
and aortic aneurysm (n=1 each) and cardiac arrest (n=3).   
  Infection 
  IRs of infections and serious infections were lower in the cumu-
lative versus the double-blind period (  table 1  ). Two cases of 
tuberculosis were documented in the cumulative period, both in 
the abatacept group; both patients discontinued. One case was 
suspected in a 55-year-old woman in the double-blind period. 
The patient did not experience any symptoms and no bacterial 
evidence of tuberculosis was found. During the LTE, tuberculo-
sis was diagnosed presumptively in a 39-year-old woman. The 
patient exhibited a response to tuberculosis therapy, although 
bronchial lavage and biopsy did not identify tuberculosis.   
  Malignancy 
  During the cumulative period, malignant neoplasms were 
reported in 24 patients (1.5 events/100 patient-years;   table 1  ). 
The three cases of lung cancer were reported during the LTE in 
patients initially randomised to abatacept; all had a history of 
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Figure 1  Clinical efﬁ  cacy and patient-reported outcomes in abatacept-treated patients. (A) Proportion of patients achieving American 
College of Rheumatology (ACR) 20, 50 and 70 responses over 3 years. (B) Proportion of patients achieving low disease activity state 
(LDAS) and Disease Activity Score 28 (DAS28) (C reactive protein (CRP))-deﬁ  ned remission over 3 years. (C) Mean change from 
baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) over 3 years. (D) Mean change from baseline in the physical 
component summary (PCS), mental component summary (MCS) and Short Form (SF)-36 individual subscales at years 1 and 3. Data 
are presented with 95% CIs for patients randomised to abatacept who entered the long-term extension (LTE) to receive ≥1 dose of 
abatacept, with available assessments at the visit of interest (as-observed population). LDAS deﬁ  ned as DAS28 (CRP) ≤3.2. DAS28-
deﬁ  ned remission deﬁ  ned as DAS28 (CRP) <2.6. At year 1, 370, 370, 373, 372, 373, 373, 373, 373, 370 and 373 patients were 
included in the PCS, MCS, physical function, role–physical, bodily pain, general health, vitality, social functioning, role–emotional and 
mental health assessments, respectively. At year 3, 308, 308, 310, 309, 309, 312, 312, 312, 309 and 312 patients were included in the 
aforementioned assessments, respectively. A change of 3.0 units in MCS and PCS was considered the minimum clinically important 
difference (MCID).
smoking. Of the two cases of lymphoma, one was reported dur-
ing the double-blind period (malignant thyroid tumour of mod-
erate intensity). The second case (non-Hodgkin’s lymphoma) 
was reported during the ﬁ  rst year of the LTE in a patient ran-
domised to placebo.   
  Autoimmune  events 
  During the cumulative period, 35 autoimmune AEs were 
reported. The most common were psoriasis, Sjögren’s syndrome 
and vasculitis (12, 4 and 4 patients, respectively).     
  Efﬁ  cacy 
  ACR  responses 
  For patients originally randomised to abatacept, the proportions 
of ACR 20, 50 and 70 responders were maintained from year 1 
to year 3 (  ﬁ  gure 1A  ).   
  Disease  activity 
  The proportion of patients achieving low disease activity state 
or DAS28-deﬁ  ned remission in the original abatacept-treated 
group increased over 3 years (  ﬁ  gure 1B  ). For DAS28-deﬁ  ned 
remission, 95% CI did not overlap for the year 1 and 3 assess-
ments (  ﬁ  gure 1B  ). Mean (SD) DAS28 (CRP) at year 3 was 3.16 
(1.18), with a mean (SE) change from baseline of –3.21 (0.08).   
    Physical function and HRQoL 
  At baseline, patients randomised to abatacept had a mean (SD) 
HAQ-DI score of 1.7 (0.6). A clinically meaningful improvement 
in physical function (HAQ-DI response) was achieved in 71.8% 
(265/369; 95% CI 67.2 to 76.4) of these patients at year 1; a 
comparable proportion achieved a HAQ-DI response at year 
3 (73.1% (255/308); 95% CI 68.1 to 78.0). Mean changes from 
baseline are shown in   ﬁ  gure 1C  . 
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component summary (MCS) at year 1 were maintained over 
3 years (  ﬁ  gure 1D  ). Of the SF-36 subscales, the greatest improve-
ment was observed in bodily pain and role–physical from base-
line to years 1 and 3 (  ﬁ  gure 1D  ).   
  Radiographic  progression 
  A total of 304/378 (81%), 293/378 (78%) and 302/378 (80%) 
abatacept-treated patients had radiographs available at base-
line and at years 1, 2 and 3, respectively, and were assessed. 
Mean changes from baseline in Genant-modiﬁ  ed Sharp scores 
were progressively reduced from baseline to years 1, 2 and 3 
(  ﬁ  gure 2A  –  C  ). Overall, scores were reduced by approximately 
50% in year 2 relative to year 1. Progression slowed even fur-
ther between years 2 and 3, with a mean change in TS of 0.25 
(p=0.022 for rate of progression in year 1 to year 2 vs year 2 
to year 3).   
  At year 1, 46% (139/304) of patients with evaluable radio-
graphs were considered non-progressors (change from baseline 
in TS ≤0). Of these 139 patients, 135 had evaluable radiographs 
at years 1 and 2; 68% (92/135) remained non-progressors at year 
2. Of the 92 patients with no progression at year 2, 91 patients 
had evaluable radiographs at years 2 and 3, of whom 76% 
(69/91) remained non-progressors at year 3. Overall, at year 3, 
40% of patients had no radiographic progression from baseline. 
Cumulative probability plots of the distribution of change in 
TS over 3 years, at yearly intervals, show an improvement in 
radiographic progression with abatacept over time (  ﬁ  gure 2D  ). 
The proportion of patients with no radiographic progression 
increased during each year of abatacept treatment.       
  DISCUSSION 
  Retention rates in long-term clinical trials provide an indication 
of the likelihood of patients continuing treatment over the long 
term in clinical practice. In the AIM trial in patients with RA 
with an inadequate response to MTX, high retention rates were 
observed over 3 years of abatacept treatment (approximately 
70%) with low discontinuation rates due to loss of efﬁ  cacy and 
safety. The yearly discontinuation rate decreased during year 
3, indicating the likelihood of patients to remain on treatment 
over the long term.  4   Retention rates observed in anti-tumour 
necrosis factor (TNF) therapy trials have been 61–75% over 
2–3 years.  5    –    7   
  IRs of SAEs, infections, serious infections, malignancies and 
autoimmune events reported during long-term abatacept expo-
sure (cumulative period for all patients who received ≥1 dose 
of abatacept regardless of original double-blind randomisation 
group) were comparable with, or lower than, those observed 
during short-term abatacept exposure (double-blind period). 
Additionally, no unique or unexpected safety signals were 
detected with long-term exposure. Although it is considered 
inappropriate to make cross-trial comparisons of IRs, it may 
be noted that IRs of AEs and SAEs in this trial were within 
the lower range of IRs reported for other biologic therapies 
(such as TNF inhibitors) in similar patient populations.  6     8    –    10   
The overall IR of cancer in the cumulative period was 1.5/100 
patient-years. This is consistent with previously reported IRs of 
malignancy in another trial of abatacept in established dis-
ease  11   and in comparator RA cohorts treated with conventional 
DMARDs (0.67–1.77/100 patient-years).  12   
  Improvements in disease status, HRQoL, physical function 
and radiographic inhibition were sustained over 3 years in a 
high proportion of patients who remained in the study and were 
treated with abatacept throughout this time. Despite the long 
disease duration and high disease burden at baseline, one-third 
Figure 2  Impact on radiographic disease progression over 3 years 
of abatacept treatment. (A) Mean change from baseline in Genant-
modiﬁ  ed Sharp total score. (B) Mean change in erosion score. 
(C) Mean change in joint space narrowing score. (D) Cumulative 
probability plot showing change from baseline in total score. 
Data based on all patients randomised to abatacept who entered the 
long-term extension to receive ≥1 dose of abatacept, from year 1–2 
(n=297)* and year 2–3 (n=295)†. Error bars represent the SEM.
  At year 3 of abatacept treatment, a clinically meaningful 
improvement of >3 units was observed in the summary scores 
and individual subscales of the SF-36. Mean improvements from 
baseline in the physical component summary (PCS) and mental 
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achieved DAS28-deﬁ  ned remission and a 70% improvement in 
signs and symptoms, while more than half of patients had low 
disease activity by year 3. For DAS28-deﬁ  ned remission, 95% 
CIs did not overlap at years 1 and 3, suggesting a signiﬁ  cant 
improvement between these time points. In addition, at year 3, 
nearly three-quarters of patients had achieved a clinically mean-
ingful improvement in physical function, and improvements in 
the SF-36 (MCS, PCS and all eight subscales) exceeded the mini-
mum clinically important difference of 3 units. 
  Increasing inhibition of radiographic progression with abata-
cept treatment has previously been reported for each year of 
treatment over 2 years in the present study.  3   Mean change in TS 
was reduced by approximately 50% in year 2 relative to year 1; 
further signiﬁ  cant inhibition was observed at year 3 relative to 
year 2. Importantly, the majority of patients with no radiographic 
progression at year 2 remained free from progression at year 3. 
Evaluation of changes in radiographic progression by cumula-
tive probability shows that the proportion of patients who 
showed either no radiographic deterioration or some improve-
ment increased during each year of abatacept treatment. 
  LTE studies should be considered in the context of their limita-
tions, as recently highlighted by Buch   et al  .  13   In this study, baseline 
demographics, although typical for this type of analysis, indicate 
a population with more active disease than is generally observed 
in clinical practice. Additionally, efﬁ  cacy analyses were based on 
as-observed analyses, which are vulnerable to the drop-out of 
patients who respond less well to treatment. However, discon-
tinuations during the LTE of this trial were relatively low, and only 
3.7% of patients discontinued due to lack of efﬁ  cacy.   
  CONCLUSION 
  Overall, these data show that abatacept has an increasing disease-
modifying effect on structural damage over time in the majority of 
patients who remain on treatment. Combined with the sustained 
clinical beneﬁ  ts, high patient retention rate and consistent safety 
proﬁ  le observed over 3 years, these data support the long-term 
use of abatacept in patients with an inadequate response to MTX. 
This population continues to be monitored in the LTE of this trial. 
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